Metastatic Bladder Cancer (includes T4 tumors)

Immunotherapy

Antibody-drug conjugate (ADC) (Chemotherapy + monoclonal antibody)

• Suitable for people with advanced bladder cancer who have already been treated with chemotherapy and another immunotherapy
• Also suitable for people who can’t have chemotherapy but have already received at least one other type of drug therapy

• These therapies work by connecting a monoclonal antibody to a chemotherapy drug. Monoclonal antibodies work as part of our immune system to recognize specific parts of the bladder cancer cell
• When a chemotherapy drug is attached to a monoclonal antibody, the chemotherapy can be targeted to bladder cancer cells so that it can find and kill these without damaging healthy cells

Usually given as a treatment for advanced bladder cancer that has continued to progress following treatment with other drug therapies, including chemotherapy and immune checkpoint inhibitors

Administered as an infusion directly into a vein

• Fatigue
• Nerve damage that causes numbness or tingling in hands and feet
• Nausea
• Taste changes
• Decreased appetite
• Diarrhea
• Rash
• Hair loss
• Dry eyes or vision changes
• Dry skin
• Itching
• High blood sugar levels